Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Tiziana Pharma
Tiziana Pharma
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Samsung Biologics signs $1.24bn biopharma manufacturing deal with Asian pharmaceutical giant
The CDMO will work with the client until the end of 2037, and will use its South Korean biomanufacturing site to serve them
Bespak and H&T Presspart announce availability of GMP pilot line for climate-friendly pMDIs
Filling line is on track to supply clinical trial batches utilising climate-friendly propellants HFA-152a and HFO-1234ze
Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma
The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone
Axol Bioscience boosts its iPSC bioassay offering with Phenocell acquisition
The acquisition will extend Axol's range of iPSC-derived cell lines, including skin and retinal cells — while also expanding its drug discovery services
How AI and GenAI will revolutionise the healthcare industry
Artificial intelligence — and particularly its newest iteration, generative artificial intelligence (GenAI) — could bring significant changes to the way we live, work and...
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Regulatory
Tiziana Life Sciences receive FDA fast track for anti-CD3 mAb to treat MS
The designation will allow Tiziana to receive priority in the review and approval process, allowing for the accelerated commercialisation of intranasal foralumab
Research & Development
Tiziana announces positive PET scan results with intranasal Foralumab in patients with na-SPMS
Five out of six patients in FDA authorised expanded access programme are showing a qualitative reduction in microglia activation (a key biomarker being observed)
Manufacturing
Tiziana Life Sciences appoints Chief Development Officer
William A. Clementi will take up the role of Chief Development Officer, which will become effective as of September 1 2023
Research & Development
Tiziana develops novel treatment for COVID-19 patients using anti-interleukin-6-receptor mAbs
Company has filed patent application in support of treatment of COVID-19 utilizing anti-il6r via inhaled delivery
Research & Development
Tiziana strengthens unique research focus by appointing Dr Kunwar Shailubhai CEO
Pharmaceutical
Tiziana Life Sciences appoints Arun Sanyal to its Scientific Advisory Board
Arun Sanyal is a professor and a key opinion leader in liver diseases such as non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Ingredients
Tiziana Life Sciences in-licenses NI-1201, a fully human anti-IL-6R monoclonal antibody
Exclusive worldwide license expands therapeutic pipeline in key immunological areas
Subscribe now